Navigation Links
The only European researcher to win this year's Early Career Bayer Hemophilia Award is Portuguese
Date:7/13/2011

Vanessa Oliveira, researcher at the Instituto de Medicina Molecular in Portugal won a prestigious and competitive Early Career Bayer Hemophilia Award. Oliveira will develop a strategy to reprogramme the immune system of hemophilia patients to avoid immune targeting of the most used clotting therapeutics. Oliveira was the only European researcher to win this award in 2010, in a total of 5 worldwide. The Portuguese researcher will receive US$170.000 to develop her project during two years.

Vanessa Oliveira will develop a strategy to reprogramme the immune system of hemophilia patients to avoid immune targeting of the most used clotting therapeutics. The treatment of hemophilia is based in the administration of laboratory produced clotting factors that the patients cannot make due to a genetic defect. However, a significant proportion of patients with severe hemophilia develop immune responses against these therapeutic clotting factors, which limits the efficacy of the treatment.

Although there have been several attempts to impair this undesired immune response, none of them has revealed efficient. Vanessa will study the causes for the limited efficacy of previously attempted methods to suppress undesirable immune response in hemophilia treatment, while developing new strategies to induce the patient's immune tolerance towards therapeutic clotting factors. This is a basic research project that will be developed in an animal model (mouse).

If results are promising, the project will be further developed to clinical studies. If Vanessas basic research is successful, it may help to improve the efficacy of current treatments. The project will be fully developed in Portugal, at the IMM's Cellular Immunology Unit, led by researcher Luis Graca.

The IMM's Cellular Immunology Unit has been developing cutting edge research in the area of immune-mediated diseases, such as asthma, transplantation and autoimmunity. The Unit's research has already resulted in the formation of a star-up company to develop a novel therapy to prevent liver transplant rejection.


'/>"/>

Contact: Marta Agostinho
marta-elisa@fm.ul.pt
351-918-486-058
Instituto de Medicina Molecular
Source:Eurekalert

Related medicine news :

1. Your e-Marketing Journey in 2010: An e-Book for Corporate Communicators Working in European Headquarters
2. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
3. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
4. Yondelis(R) Receives Five New Approvals Outside the European Economic Area
5. Promega Maxwell 16 IVD System CE Marked to the European Union IVD Directive Delivers Combined Solution for Infectious Disease
6. The European Medicines Agency Completes Validation Stage for InterMunes Marketing Authorization Application for pirfenidone
7. European hematologist receives award to conduct research in US
8. European collaboration seeks to create World Wide Web for robots
9. HCL Thames Medics says more locum doctors could help address European Working Time Directive shortage
10. Third European Novel Food Approval Received by Tahitian Noni International
11. European Urology: Editorial about REDUCE trial underlines value of dutasteride
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: